The taccalonolides, novel microtubule stabilizers, and γ-radiation have additive effects on cellular viability

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 104-111

  Risinger, April L ^a   Natarajan, Mohan ^b   Thomas, Charles R ^a   Mooberry, Susan L ^a  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Radiation; Antimitotic; Microtubule stabilizer; Radio sensitizer; Taccalonolide

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; TACCALONOLIDE A; TACCALONOLIDE E; UNCLASSIFIED DRUG;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL VIABILITY; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; FLUORESCENCE MICROSCOPY; GAMMA RADIATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION;

BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; GAMMA RAYS; HUMANS; MICROTUBULES; MOUTH NEOPLASMS; STEROIDS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 79957437628     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.022     Document Type: Article

References (23)

1. Specenier P., Vermorken J.B. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr. Opin. Oncol. 2007, 19:195-201.
2. Specenier P.M., Vermorken J.B. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?. Cancer Lett. 2007, 256:166-177.
3. Yang E.S., Murphy B.M., Chung C.H., Netterville J.L., Burkey B.B., Gilbert J., Yarbrough W.G., Sinard R., Cmelak A.J. Evolution of clinical trials in head and neck cancer. Crit. Rev. Oncol. Hematol. 2009, 71:29-42.
4. Mason K.A., Kishi K., Hunter N., Buchmiller L., Akimoto T., Komaki R., Milas L. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin. Cancer Res. 1999, 5:4191-4198.
5. Kim J.C., Kim J.S., Saha D., Cao Q., Shyr Y., Choy H. Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. Radiother. Oncol. 2003, 68:305-313.
6. Kim J.S., Amorino G.P., Pyo H., Cao Q., Price J.O., Choy H. The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51:525-534.
7. Sinclair W.K. Cyclic X-ray responses in mammalian cells in vitro. Radiat. Res. 1968, 33:620-643.
8. Hofstetter B., Vuong V., Broggini-Tenzer A., Bodis S., Ciernik I.F., Fabbro D., Wartmann M., Folkers G., Pruschy M. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin. Cancer Res. 2005, 11:1588-1596.
9. Steren A., Sevin B.U., Perras J., Ramos R., Angioli R., Nguyen H., Koechli O., Averette H.E. Taxol as a radiation sensitizer: a flow cytometric study. Gynecol. Oncol. 1993, 50:89-93.
10. Posner M.R., Hershock D.M., Blajman C.R., Mickiewicz E., Winquist E., Gorbounova V., Tjulandin S., Shin D.M., Cullen K., Ervin T.J., Murphy B.A., Raez L.E., Cohen R.B., Spaulding M., Tishler R.B., Roth B., Viroglio Rdel C., Venkatesan V., Romanov I., Agarwala S., Harter K.W., Dugan M., Cmelak A., Markoe A.M., Read P.W., Steinbrenner L., Colevas A.D., Norris C.M., Haddad R.I. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 2007, 357:1705-1715.
11. Schoffski P., Weihkopf T., Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Anticancer Res. 1998, 18:4751-4756.
12. Dreyfuss A.I., Clark J.R., Norris C.M., Rossi R.M., Lucarini J.W., Busse P.M., Poulin M.D., Thornhill L., Costello R., Posner M.R. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1996, 14:1672-1678.
13. Nabell L., Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin. Oncol. 2003, 30:89-93.
14. Simoens C., Lardon F., Pauwels B., De Pooter C.M., Lambrechts H.A., Pattyn G.G., Breillout F., Vermorken J.B. Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 2008, 8:65.
15. Akashi Y., Okamoto I., Suzuki M., Tamura K., Iwasa T., Hisada S., Satoh T., Nakagawa K., Ono K., Fukuoka M. The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo. Br. J. Cancer 2007, 96:1532-1539.
16. Tinley T.L., Randall-Hlubek D.A., Leal R.M., Jackson E.M., Cessac J.W., Quada J.C., Hemscheidt T.K., Mooberry S.L. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res. 2003, 63:3211-3220.
17. Risinger A.L., Jackson E.M., Polin L.A., Helms G.L., LeBoeuf D.A., Joe P.A., Hopper-Borge E., Luduena R.F., Kruh G.D., Mooberry S.L. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 2008, 68:8881-8888.
18. Risinger A.L., Mooberry S.L. Taccalonolides: novel microtubule stabilizers with clinical potential. Cancer Lett. 2010, 291:14-19.
19. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 1975, 66:188-193.
20. Maddox A.S., Burridge K. RhoA is required for cortical retraction and rigidity during mitotic cell rounding. J. Cell Biol. 2003, 160:255-265.
21. St John L.S., Sauter E.R., Herlyn M., Litwin S., Adler-Storthz K. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther. 2000, 7:749-756.
22. Simoens C., Pauwels B., Vermorken J.B., Pattyn G.G., Lambrechts H.A., Breillout F., Lardon F. Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro. Cancer Chemother. Pharmacol. 2008, 62:183-193.
23. Pauwels B., Korst A.E., de Pooter C.M., Pattyn G.G., Lambrechts H.A., Baay M.F., Lardon F., Vermorken J.B. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother. Pharmacol. 2003, 51:221-226.